Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biochimica Et Biophysica Acta|November 13, 2007
Targeting phosphoinositide 3-kinase: moving towards therapyRomina Marone, Vladimir Cmiljanovic, Bernd Giese, et al.
Non-Coding RNA|April 30, 2021
Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of TranslationNicolas Munz, Luciano Cascione, Luca Parmigiani, et al.
Molecular Cancer Research : MCR|April 18, 2009
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitorsRomina Marone, Dominik Erhart, Ann C Mertz, et al.
Hematological Oncology|March 5, 2025
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC SubtypeChiara Tarantelli, Omar Kayali, Elisa Civanelli, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Cancers|March 28, 2024
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid TumorsFilip Janku, Grace M Choong, Mateusz Opyrchal, et al.
Journal of Medicinal Chemistry|August 23, 2017
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in OncologyFlorent Beaufils, Natasa Cmiljanovic, Vladimir Cmiljanovic, et al.
NPJ Vaccines|October 30, 2024
High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamstersMartin Joseph Lett, Fabian Otte, David Hauser, et al.
Nature Communications|March 10, 2017
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic interventionThomas Bohnacker, Andrea E Prota, Florent Beaufils, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Pageof 2